Reston, VA — A new molecular imaging technique that pairs a novel tracer with a next-generation PET/CT scanner can identify neuroblastoma in children with high sensitivity, requiring a scan time of only minutes and no sedation or anesthesia. With its ability to accurately diagnose neuroblastoma, this technique, known as 18F-MFBG LAFOV PET/CT, has the potential to impact therapeutic decision-making for children with this disease. This research was published in the August issue of The Journal of Nuclear Medicine.
Neuroblastoma is the most common extracranial solid tumor in children, with an overall survival of 70 percent. For decades, 123I-MIBG SPECT/CT has been the standard of care for initial staging, response assessment, and frequently used follow-up of neuroblastoma. The 123I-MIBG SPECT/CT scanning procedure is a two-day protocol. Sedation or general anesthesia is frequently used because the patients are predominantly infants and due to the lengthy scan time, often more than two hours.
“For young children undergoing molecular imaging, less exposure to radiation and the avoidance of sedation or general anesthesia is very important,” said Lise Borgwardt, MD, PhD, senior consultant in pediatric nuclear medicine at Copenhagen University Hospital-Rigshospitalet, in Copenhagen, Denmark. “In our study, we used the tracer 18F-MFBG which requires only a one-day protocol, at the long-axial-field-of-view (LAFOV) PET/CT scanner, which has a sensitivity about 10 times higher than a digital PET/CT scanner. We then compared this technique with 123I-MIBG SPECT/CT to determine its diagnostic value and feasibility.”
The study included 10 children with neuroblastoma who received 123I-MIBG SPECT/CT followed by 18F-MFBG LAFOV PET/CT. Masked readers independently scored the 123I-MIBG and 18F-MFBG scans for the presence of any pathologic lesions. SIOPEN and Curie scores (semi-quantitative systems used to assess metastatic disease burden) were also calculated.
None of the children required sedation or general anesthesia with 18F-MFBG LAFOV PET/CT, whereas 80 percent had general anesthesia with 123I-MIBG SPECT/CT. In addition, a PET acquisition time of only two minutes without motion artifacts was required for reconstruction to provide a clinically useful image with 18F-MFBG LAFOV PET/CT.
Eighty percent of 18F-MFBG LAFOV PET/CT scans revealed more lesions than 123I-MIBG SPECT/CT scans and 20 percent revealed the same number of lesions. In 18F-MFBG LAFOV PET/CT scans, the SIOPEN score was higher in 50 percent of the cases, and the Curie score was higher in 70 percent of the cases. Intraspinal involvement, retroperitoneal lymph node involvement, and bone marrow involvement were diagnosed with much higher precision with 18F-MFBG LAFOV PET/CT.
“A scan with a much higher sensitivity can find very small lesions and the exact extension in the body and can be extremely beneficial in determining the right course of treatment,” said Borgwardt. “The fact that these scans can be performed without anesthesia or sedation, and at a lower radiation dose is a big step forward for the children, parents, and the healthcare system in general.”
The authors of “Performing[18F]MFBG Long–Axial-Field-of-View PET/CT Without Sedation or General Anesthesia for Imaging of Children with Neuroblastoma” include Lise Borgwardt, Kim Francis Andersen, Jacob Madsen, Nicholas Gillings, Marie Øbro Fosbøl, Charlotte Lund Denholt, Ida Nymann Petersen, Louise Sørup Sørensen, Lotte Hahn Enevoldsen, Peter Sandor Oturai, Helle Hjort Johannesen, Liselotte Højgaard, Christina Schulze, Eunice Saxtoft, Flemming Anderson, and Barbara Malene Fischer, Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital–Rigshospitalet, Copenhagen, Denmark; and Jesper Brok, Department of Paediatrics, Copenhagen University Hospital–Rigshospitalet, Copenhagen, Denmark.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or [email protected].
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 16 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Contact
Rebecca Maxey
Society of Nuclear Medicine and Molecular Imaging
[email protected]
Office: 703-652-6772